title: Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
abstract: This retrospective study aimed to compare the therapeutic response, including side effects, for oral baclofen versus oral tizanidine therapy with adjuvant botulinum toxin type A in a group of 64 pediatric patients diagnosed with static encephalopathy and spastic equinus foot deformity. Following botulinum toxin A treatment, clinical improvement led to the gradual reduction of baclofen or tizanidine dosing to one-third of the former dose. Gross Motor Functional Measure and Caregiver Health Questionnaire scores were markedly elevated post-botulinum toxin A treatment, with scores for the tizanidine (Gross Motor Functional Measure: 74.45 ± 3.72; Caregiver Health Questionnaire: 72.43 ± 4.29) group significantly higher than for the baclofen group (Gross Motor Functional Measure: 68.23 ± 2.66; Caregiver Health Questionnaire: 67.53 ± 2.67, P < .001). These findings suggest that the combined use of botulinum toxin A and a low dose of tizanidine in treating children with cerebral palsy appears to be more effective and has fewer side effects versus baclofen with adjuvant botulinum toxin A.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Division of Pediatric Neurology, University of Gaziantep, Gaziantep, Turkey dai.alper@gmail.com.
authors.forename: Alper I
authors.initials: AI
authors.lastname: Dai
authors.affiliation: Department of Biochemistry, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey.
authors.forename: Sefika N
authors.initials: SN
authors.lastname: Aksoy
authors.affiliation: Department of Medical Pharmacology, Faculty of Medicine, University of Gaziantep, Gaziantep, Turkey.
authors.forename: Abdullah T
authors.initials: AT
authors.lastname: Demiryürek
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D001418:Baclofen / Q000008:administration & dosage* / Q000009:adverse effects; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D002547:Cerebral Palsy / Q000150:complications / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003000:Clonidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination / Q000009:adverse effects; D004863:Equinus Deformity / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009128:Muscle Spasticity / Q000150:complications / Q000188:drug therapy; D009465:Neuromuscular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D009465:Neuromuscular Agents; C023754:tizanidine; D019274:Botulinum Toxins, Type A; D001418:Baclofen; D003000:Clonidine
keywords: adverse effect; baclofen; botulinum toxin; cerebral palsy; tizanidine